The use of 3D printing prior to transaortic valve replacement (TAVR) procedures may help cardiac surgeons to predict areas where an ill-fitting stent frame could lead to paravalvular leaks (PVLs), a small retrospective study has shown.
Neither intravenous (IV) sodium bicarbonate nor oral N-acetylcysteine (NAC) is better than IV saline in reducing 90-day events or contrast-associated acute kidney injury (AKI) in the PRESERVE substudy, suggesting that normal saline hydration is the default therapy for contrast-induced AKI.
The hybrid approach to percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) yielded good success rates in the hands of experienced operators, the PROGRESS CTO* Registry study has shown, offering important benchmarking for discussion of the risk-benefit ratio of CTO PCI.
Transcatheter mitral valve repair with the MitraClip device significantly improves the severity of mitral regurgitation (MR), functional status, and quality of life of patients with MR and who were at prohibitive risk for surgery, according to the MitraClip Post-Approval Study 1 (PAS1) presented at SCAI 2018.
Biologic therapy for treating psoriasis, in particular anti-TNF agents, can also help reduce coronary plaque besides suppressing inflammation in the skin, suggests a study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego, California, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.